Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study

Blood. 1995 Feb 1;85(3):824-8.

Abstract

We studied the value of leukocyte depletion of platelet transfusions for the prevention of secondary human leukocyte antigen (HLA)-alloimmunization in patients with a high-risk of prior immunization induced by pregnancies. Seventy-five female patients with hematologic malignancies (mostly acute leukemia) and a history of pregnancy were randomized to receive either standard random single-donor platelet transfusions (mean leukocytes, 430 x 10(6) per transfusion) or leukocyte-depleted random single-donor platelet transfusions. Leukocyte depletion to less than 5 x 10(6) leukocytes per platelet transfusion (mean leukocytes, 2 x 10(6) per transfusion) was achieved by filtration. Of the 62 evaluable patients, refractoriness to random donor platelets occurred in 41% (14 of 34) of the patients in the standard group and in 29% (8 of 28) of the patients in the filtered group (P = .52); anti-HLA antibodies developed in 43% (9 of 21) of individuals in the standard group and 44% (11 of 25) of cases in the filtered group. The time toward refractoriness and development of anti-HLA antibodies was similar for both groups. We conclude that leukocyte depletion of random single-donor platelet products to less than 5 x 10(6) per transfusion does not reduce the incidence of refractoriness to random donor platelet transfusion because of boostering of anti-HLA antibodies.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Female
  • HLA Antigens / immunology
  • Humans
  • Isoantibodies / blood*
  • Isoantigens / immunology
  • Leukemia / therapy*
  • Leukemia, Myeloid, Acute / therapy
  • Leukocytes / cytology*
  • Leukocytes / immunology
  • Life Tables
  • Lymphoma, Non-Hodgkin / therapy*
  • Middle Aged
  • Multiple Myeloma / therapy*
  • Myelodysplastic Syndromes / therapy*
  • Platelet Transfusion*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Pregnancy
  • Prospective Studies

Substances

  • HLA Antigens
  • Isoantibodies
  • Isoantigens